Bird Flu Vaccine Trial Aims to Protect Endangered Seals

Wildlife veterinarians are currently testing bird flu vaccines on marine mammals due to the significant losses these animals have experienced during the ongoing global outbreak. The initial trial, which commenced in July, is a small-scale study. It involves only six northern elephant seals that were already undergoing rehabilitation at the Marine Mammal Center in Sausalito, California.

Researchers are optimistic about the potential of the vaccine. If the results from the initial trial are favorable, they plan to quickly begin vaccinating wild Hawaiian monk seals. This species is classified as endangered, and experts are concerned that the virus could decimate their population.

The wild population of Hawaiian monk seals is estimated to be only 1,600 individuals. They primarily inhabit a remote chain of Hawaiian islands. The arrival of migrating birds in the coming weeks poses a significant threat, as these birds could potentially carry the virus.

Dr. Sophie Whoriskey, the associate director of Hawai’i Conservation Medicine at the Marine Mammal Center, emphasized the urgency of the situation. She stated that the virus is actively spreading. The Marine Mammal Center is leading the trial in collaboration with the National Oceanic and Atmospheric Administration.

A decision regarding the vaccination of monk seals will be made in consultation with the National Oceanic and Atmospheric Administration. Rachel Hager, a spokeswoman for NOAA, deferred questions about the trial to the Marine Mammal Center. She indicated that NOAA would consider the center's findings as they work to protect the survival of endangered marine species.